MA38656A1 - Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose - Google Patents

Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Info

Publication number
MA38656A1
MA38656A1 MA38656A MA38656A MA38656A1 MA 38656 A1 MA38656 A1 MA 38656A1 MA 38656 A MA38656 A MA 38656A MA 38656 A MA38656 A MA 38656A MA 38656 A1 MA38656 A1 MA 38656A1
Authority
MA
Morocco
Prior art keywords
inhibitor
cancer
mps
kinase
treatment
Prior art date
Application number
MA38656A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48576906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38656A1 publication Critical patent/MA38656A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose. La présente invention concerne en outre l'utilisation de ladite combinaison pour le traitement d'un cancer, en particulier du cancer du pancréas, d'un glioblastome, du cancer de l'ovaire, d'un carcinome pulmonaire non à petites cellules, du cancer du sein et/ou du cancer gastrique.
MA38656A 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose MA38656A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171517 2013-06-11
PCT/EP2014/061772 WO2014198645A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Publications (1)

Publication Number Publication Date
MA38656A1 true MA38656A1 (fr) 2018-05-31

Family

ID=48576906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38656A MA38656A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Country Status (16)

Country Link
US (1) US20160128988A1 (fr)
EP (1) EP3007692A1 (fr)
JP (1) JP2016520665A (fr)
KR (1) KR20160018534A (fr)
CN (1) CN105283178A (fr)
AU (1) AU2014280354A1 (fr)
CA (1) CA2914742A1 (fr)
CL (1) CL2015003585A1 (fr)
EA (1) EA201600003A1 (fr)
HK (1) HK1219879A1 (fr)
MA (1) MA38656A1 (fr)
MX (1) MX2015017120A (fr)
PH (1) PH12015502757A1 (fr)
SG (1) SG11201509350RA (fr)
TN (1) TN2015000543A1 (fr)
WO (1) WO2014198645A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160156A1 (es) * 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
BR112018071023A2 (pt) * 2016-04-15 2019-02-05 Felicitex Therapeutics Inc combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
CN106117202B (zh) * 2016-06-29 2018-06-26 四川大学华西医院 具有抗肿瘤活性的[1,2,4]三唑并[1,5-a]吡啶衍生物晶型
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
WO2023165603A1 (fr) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Inhibiteur d'adn-pk et son utilisation en combinaison

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
EP1201666A3 (fr) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones à chaine latérale modifiée
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
CA2299608A1 (fr) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
AU738576B2 (en) 1997-12-04 2001-09-20 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
EP2343294A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
US20140120087A1 (en) * 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (fr) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
BR112015000308A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020043A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer

Also Published As

Publication number Publication date
CA2914742A1 (fr) 2014-12-18
PH12015502757A1 (en) 2016-03-21
EP3007692A1 (fr) 2016-04-20
WO2014198645A1 (fr) 2014-12-18
JP2016520665A (ja) 2016-07-14
AU2014280354A1 (en) 2015-12-03
US20160128988A1 (en) 2016-05-12
KR20160018534A (ko) 2016-02-17
TN2015000543A1 (en) 2017-04-06
CL2015003585A1 (es) 2016-07-08
CN105283178A (zh) 2016-01-27
HK1219879A1 (zh) 2017-04-21
EA201600003A1 (ru) 2016-06-30
SG11201509350RA (en) 2015-12-30
MX2015017120A (es) 2016-10-05

Similar Documents

Publication Publication Date Title
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EP3934645A4 (fr) Utilisation du catequentinib (anlotinib) en combinaison avec une chimiothérapie standard ou une immunothérapie standard pour le traitement du cancer
EP3578984A3 (fr) Biomarqueurs salivaires pour cancer de la bouche
MA39034A1 (fr) Composés de quinoline sélectivement substitués
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MY173126A (en) Arylquinazolines
IN2014DN05885A (fr)
MA40061A (fr) Compositions immunogènes à base de listeria pour provoquer des réponses anti-tumorales
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EA201690244A1 (ru) Ингибиторы киназ на основе простых ариловых эфиров
EP3356684A4 (fr) Combinaison de bloc collecteur, de boîtier de soupape et d'ensemble tiroir de commande pour bloc collecteur
MX372823B (es) Derivados de ácido borónico.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
MX388832B (es) Deteccion especifica de isoformas de clusterina.
BR112015018433A2 (pt) indicador de desgaste em um sistema composto feito de tijolos de cerâmica à prova de fogo
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2015010776A (es) Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos.
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées